heme-oxygenase-1-protein

Migration, Crosslink

📖

heme-oxygenase-1-protein

active

wiki page Created: 2026-04-02T07:19:15 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-heme-oxygenase-1-protein

📖 Wiki Page

protein2541 wordssynced 2026-04-02

Heme Oxygenase-1 (HO-1) Protein

Overview

Heme oxygenase-1 (HO-1, encoded by the HMOX1 gene) is a 32 kDa inducible enzyme that catalyzes the rate-limiting step in heme degradation, converting heme into biliverdin, iron (Fe²⁺), and carbon monoxide (CO). Originally characterized for its role in erythrocyte turnover and iron recycling, HO-1 has emerged as a critical cytoprotective protein in the nervous system with profound implications for neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), and others. [@schipper2019]

HO-1 belongs to the heme oxygenase family which includes two isoforms: the inducible HO-1 (HMOX1) and the constitutive HO-2 (HMOX2). While HO-2 is primarily expressed in the brain and testis, HO-1 is expressed at low levels under normal physiological conditions but can be dramatically induced by cellular stress, making it a central player in the cellular stress response. [@nath2019]

| Property | Value |
|----------|-------|
| Protein Name | Heme Oxygenase-1 (HO-1) |
| Gene Symbol | HMOX1 |
| Chromosomal Location | 22q12.3 |
| NCBI Gene ID | 3162 |
| UniProt ID | P09601 (HO1_HUMAN) |
| Molecular Weight | 32 kDa |
| Subcellular Location | Endoplasmic reticulum, mitochondria |
| Inducers | Heme, oxidative stress, cytokines, heat shock |
| Inhibitors | SnPP, ZnPP, synthetic metalloporphyrins |

</div>

...

Heme Oxygenase-1 (HO-1) Protein

Overview

Heme oxygenase-1 (HO-1, encoded by the HMOX1 gene) is a 32 kDa inducible enzyme that catalyzes the rate-limiting step in heme degradation, converting heme into biliverdin, iron (Fe²⁺), and carbon monoxide (CO). Originally characterized for its role in erythrocyte turnover and iron recycling, HO-1 has emerged as a critical cytoprotective protein in the nervous system with profound implications for neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), and others. [@schipper2019]

HO-1 belongs to the heme oxygenase family which includes two isoforms: the inducible HO-1 (HMOX1) and the constitutive HO-2 (HMOX2). While HO-2 is primarily expressed in the brain and testis, HO-1 is expressed at low levels under normal physiological conditions but can be dramatically induced by cellular stress, making it a central player in the cellular stress response. [@nath2019]

| Property | Value |
|----------|-------|
| Protein Name | Heme Oxygenase-1 (HO-1) |
| Gene Symbol | HMOX1 |
| Chromosomal Location | 22q12.3 |
| NCBI Gene ID | 3162 |
| UniProt ID | P09601 (HO1_HUMAN) |
| Molecular Weight | 32 kDa |
| Subcellular Location | Endoplasmic reticulum, mitochondria |
| Inducers | Heme, oxidative stress, cytokines, heat shock |
| Inhibitors | SnPP, ZnPP, synthetic metalloporphyrins |

</div>

Structure and Catalytic Mechanism

Protein Architecture

HO-1 is a homodimeric enzyme with each monomer consisting of:

N-terminal transmembrane helix (residues 1-23): Anchors the protein to the endoplasmic reticulum membrane
Heme binding pocket (residues 24-200): Contains the catalytic site where heme degradation occurs
Proximal helix: Provides the iron ligand for heme binding
Distal helix: Forms the substrate access channel
C-terminal regulatory domain: Modulates enzyme activity and protein interactions

The crystal structure of HO-1 reveals a unique "sheltered" binding pocket where the heme molecule is sandwiched between two helical segments, with the catalytic Asp140 and His25 playing critical roles in the oxygenation reaction. [@alam2022]

Catalytic Reaction

The HO-1 catalyzed reaction proceeds in three steps:

Heme oxygenation: Fe²⁺-heme + O₂ + NADPH + H₂O → biliverdin + Fe²⁺ + CO + NADP⁺ + H₂O

Biliverdin reduction: Biliverdin + NADPH → bilirubin (via biliverdin reductase)

Iron release: Ferrous iron (Fe²⁺) is either sequestered by ferritin or released

The reaction requires NADPH-cytochrome P450 reductase (CPR) as an electron donor, making HO-1 part of the microsomal monooxygenase system. Importantly, the products of heme catabolism—biliverdin/bilirubin, CO, and ferritin-bound iron—all possess biological activities relevant to neuroprotection. [@schipper2019]

Normal Function in the Nervous System

Cytoprotective Functions

Under normal physiological conditions, HO-1 is expressed at low levels in the brain but serves critical homeostatic functions:

Antioxidant Defense: HO-1 is a key component of the Nrf2-ARE antioxidant response pathway. The Nrf2 transcription factor translocates to the nucleus upon oxidative stress and binds to the antioxidant response element (ARE) in the HMOX1 promoter, dramatically upregulating HO-1 expression. This creates a feedback loop where oxidative stress induces HO-1, and the products of heme degradation (particularly biliverdin and bilirubin) provide antioxidant protection. [@alam2022]

Anti-inflammatory Activity: HO-1 exerts potent anti-inflammatory effects through multiple mechanisms:

Inhibition of NF-κB signaling pathway
Suppression of pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6)
Promotion of anti-inflammatory M2 microglial phenotype
Modulation of T-cell responses

The CO produced by HO-1 activity acts as a signaling molecule that inhibits inflammatory responses through modulation of MAPK pathways and inhibition of NF-κB. [@barsoum2019]

Mitochondrial Protection: HO-1 localizes to mitochondria in neurons and astrocytes, where it:

Maintains mitochondrial membrane potential
Preserves electron transport chain function
Prevents mitochondrial permeability transition
Promotes mitophagy to remove damaged mitochondria

This mitochondrial localization is particularly relevant to neurodegenerative diseases, where mitochondrial dysfunction is a central pathogenic mechanism. [@chen2023]

Iron Homeostasis: By degrading heme and promoting ferritin expression, HO-1 plays a crucial role in maintaining iron balance in the brain. The induction of HO-1 leads to increased ferritin synthesis, which sequesters potentially toxic free iron, preventing iron-catalyzed oxidative damage. This is particularly important in brain regions susceptible to iron accumulation and neurodegeneration. [@kim2023]

Cellular Distribution in the Brain

In the normal brain, HO-1 expression varies by cell type:

Neurons: Low basal expression, rapidly inducible under stress
Astrocytes: Constitutive expression at moderate levels, strongly induced
Microglia: Low basal expression, highly inducible by inflammatory stimuli
Oligodendrocytes: Limited expression, increases in demyelinating conditions
Endothelial cells: Expresses HO-1 at blood-brain barrier interfaces

The inducible nature of HO-1 makes it a sentinel of cellular stress across all neural cell types, positioning it as a potential therapeutic target in neurodegeneration. [@schipper2000]

Role in Alzheimer's Disease

HO-1 Expression in AD Brain

Multiple studies have documented elevated HO-1 expression in [Alzheimer's disease](/diseases/alzheimers-disease) brains. Immunohistochemical analyses reveal:

Increased HO-1 immunoreactivity in hippocampus, cortex, and amygdala
Localization to neurons, astrocytes, and microglia surrounding amyloid plaques
Correlation with disease severity
Co-localization with hyperphosphorylated [tau](/proteins/tau) pathology

The upregulation of HO-1 in AD is interpreted as a compensatory neuroprotective response to oxidative stress, amyloid-beta ([Aβ](/proteins/amyloid-beta)) toxicity, and neuroinflammation. However, chronic HO-1 induction may become maladaptive, contributing to disease progression. [@song2020]

Mechanisms of HO-1 in AD Pathogenesis

Amyloid-beta Interaction: Aβ peptides directly induce HO-1 expression in neurons and glia through oxidative stress-dependent mechanisms. The HO-1 induction is part of a broader cellular stress response, but the enzyme's activity may influence Aβ metabolism:

Biliverdin and bilirubin can inhibit Aβ aggregation in vitro
CO signaling may modulate amyloid precursor protein (APP) processing
HO-1-induced iron release could influence Aβ-induced oxidative stress

Oxidative Stress Modulation: AD brains exhibit severe oxidative damage to lipids, proteins, and DNA. HO-1 provides antioxidant protection through:

Production of bilirubin, a potent lipid-soluble antioxidant
Induction of ferritin, sequestering free iron
CO-mediated inhibition of ROS-generating enzymes

Neuroinflammation: Chronic neuroinflammation is a hallmark of AD. HO-1 exerts anti-inflammatory effects that may be beneficial:

Suppression of microglial activation
Reduction in pro-inflammatory cytokine expression
Promotion of anti-inflammatory phenotype

However, sustained HO-1 activity may also have negative consequences, including promotion of pro-oxidant iron release when ferritin induction is insufficient. [@peacock2023]

Genetic Associations

Polymorphisms in the HMOX1 gene have been associated with AD risk:

(GT)n repeat polymorphisms: Affect HMOX1 transcriptional activity
Promoter variants: Influence inducibility under stress
Functional SNPs: May alter enzyme expression levels

Studies have reported inconsistent associations, likely due to population differences and gene-environment interactions. [@goetzl2020]

Therapeutic Implications

HO-1 represents a promising therapeutic target for AD:

HO-1 inducers: Natural compounds (curcumin, sulforaphane) and pharmacological agents can upregulate HO-1 expression
CO-releasing molecules: CO donors may provide neuroprotective effects without heme degradation
Bilirubin analogs: Synthetic antioxidants based on biliverdin/bilirubin structures
Gene therapy: AAV-mediated HO-1 delivery has shown promise in preclinical models

Role in Parkinson's Disease

HO-1 in PD Pathogenesis

[Parkinson's disease](/diseases/parkinsons-disease) is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta and the presence of [Lewy bodies](/mechanisms/alpha-synuclein-aggregation) containing [alpha-synuclein](/proteins/alpha-synuclein). HO-1 is profoundly upregulated in PD brains:

Markedly elevated HO-1 in substantia nigra neurons
Co-localization with Lewy bodies
Association with disease severity
Correlation with dopaminergic neuron loss

The pattern of HO-1 induction in PD suggests it plays a complex role in disease pathogenesis—initially protective but potentially contributing to iron dysregulation and progression with chronic activation. [@lin2007]

Mechanisms of HO-1 in PD

Alpha-synuclein Aggregation: HO-1 expression is induced by alpha-synuclein aggregates:

Protein aggregates activate cellular stress pathways
Oxidative stress from aggregates triggers HO-1 induction
HO-1 may modulate alpha-synuclein aggregation and toxicity

Mitochondrial Dysfunction: PD involves complex I deficiency and mitochondrial dysfunction:

HO-1 protects against mitochondrial oxidative damage
CO preserves mitochondrial complex activity
Bilirubin maintains mitochondrial membrane potential

Dopaminergic Neuron Vulnerability: Substantia nigra neurons are particularly susceptible:

High iron content makes them vulnerable to oxidative stress
HO-1 induction is particularly prominent in these neurons
The balance between neuroprotection and iron release is critical

Iron Dysregulation: PD involves regional iron accumulation:

HO-1 can release iron during heme catabolism
Chronic HO-1 activity may contribute to iron load
Ferritin induction may be insufficient to sequester released iron

Therapeutic Targeting in PD

HO-1-based therapies for PD include:

Pharmacological inducers: Flavonoids, statins, and nutraceuticals
Gene therapy: AAV-HO-1 delivery in preclinical models showed promise
CO-releasing molecules: Low-dose CO may provide neuroprotection
Combination approaches: HO-1 inducers with antioxidants or anti-inflammatory agents [@takahashi2017]

Role in Amyotrophic Lateral Sclerosis

HO-1 Expression in ALS

[Amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) is a fatal neurodegenerative disorder affecting upper and lower motor neurons. HO-1 is upregulated in ALS:

Increased expression in spinal cord motor neurons
Localization to activated astrocytes and microglia
Correlation with disease progression
Detection in CSF as a potential biomarker

The induction of HO-1 in ALS represents a cellular stress response to motor neuron injury, protein aggregation, and neuroinflammation. [@kikuchi2022]

Mechanisms

Motor Neuron Vulnerability: Motor neurons exhibit specific vulnerabilities:

High metabolic demand makes them susceptible to oxidative stress
Protein aggregation triggers cellular stress responses
HO-1 induction reflects attempts at neuroprotection

Glial Contributions: Astrocytes and microglia contribute to disease progression:

Dysregulated neuroinflammation in ALS
Astrocytic HO-1 may influence motor neuron survival
Microglial HO-1 modulates neuroinflammation

Therapeutic Potential: Strategies to modulate HO-1 in ALS:

Enhancement of beneficial HO-1 effects
Prevention of maladaptive chronic activation
Combination with other neuroprotective approaches

Role in Other Neurodegenerative Conditions

Stroke and Cerebral Ischemia

HO-1 is rapidly induced following cerebral ischemia-reperfusion injury:

Protective effects in animal models of stroke
CO-mediated vasodilation improves cerebral blood flow
Anti-inflammatory actions reduce post-ischemic damage
HO-1 gene therapy shows promise in preclinical studies [@chang2021]

Traumatic Brain Injury

Following [traumatic brain injury](/diseases/traumatic-brain-injury), HO-1 is induced as part of the injury response:

Dual roles: initial protection versus chronic dysregulation
Therapeutic window for HO-1 modulation
Potential as a biomarker for injury severity [@wu2021]

Huntington's Disease

HO-1 expression is altered in [Huntington's disease](/diseases/huntingtons-disease):

Upregulation in affected brain regions
Relationship to mutant huntingtin toxicity
Potential therapeutic target

Multiple Sclerosis and Demyelination

In demyelinating diseases, HO-1 is involved in:

Oligodendrocyte protection
Myelin repair processes
Modulation of neuroinflammation

Ferroptosis and HO-1

Recent research has revealed important connections between HO-1 and [ferroptosis](/mechanisms/ferroptosis), a form of regulated cell death characterized by iron-dependent lipid peroxidation:

HO-1 as a Double-Edged Sword:

Acute HO-1 induction can prevent ferroptosis by reducing labile iron and producing antioxidant biliverdin
Chronic HO-1 activation can promote ferroptosis through iron release
The timing and context of HO-1 activation determines its effects

Therapeutic Implications:

Short-term HO-1 activation may be protective
Iron chelation combined with HO-1 modulation
Targeting the balance between protection and iron release [@xinhua2022]

Therapeutic Targeting Strategies

Pharmacological HO-1 Inducers

Several classes of compounds can upregulate HO-1 expression:

Natural Products:

Curcumin: Strong HO-1 inducer via Nrf2 activation
Sulforaphane: Broccoli-derived Nrf2 activator
Resveratrol: Sirt1-mediated HO-1 upregulation
Flavonoids: Wide range of HO-1 inducing activity [@chung2018]

Pharmacological Agents:

Statins: HMG-CoA reductase inhibitors with HO-1 inducing properties
Dimethyl fumarate: Approved for MS, activates Nrf2-HO-1 pathway
Aspirin: Low-dose induces HO-1 in endothelial cells

CO-Releasing Molecules (CORMs)

CO-releasing molecules provide the beneficial effects of HO-1 activity without heme degradation:

Metal-carbonyl based CORMs
Light-activated CORMs
Enzyme-triggered CO release

CO mediates:

Anti-inflammatory signaling
Anti-apoptotic effects
Vasodilation
Mitochondrial protection [@yoshikawa2020]

Gene Therapy Approaches

Viral vector-mediated HO-1 delivery:

AAV-based gene therapy shows promise in preclinical models
Targeted delivery to affected brain regions
Controlled expression systems
Combination with other therapeutic genes

Challenges and Considerations

Biphasic Nature of HO-1: The effects of HO-1 are context-dependent:

Acute induction: Protective
Chronic dysregulation: Potentially harmful
Iron release vs. antioxidant protection balance

Cell-Type Specific Effects: HO-1 in different cell types may have distinct effects:

Neuronal vs. astrocytic vs. microglial HO-1
Therapeutic targeting must consider cell specificity

Systemic vs. CNS Effects: Peripheral HO-1 induction may have indirect CNS effects:

Peripheral anti-inflammatory actions
Modulation of gut-brain axis
Systemic iron metabolism

Biomarker Potential: HO-1 has potential as:

Disease progression biomarker
Therapeutic response indicator
Diagnostic tool in certain conditions [@caldi2022]

Key Publications and Clinical Evidence

[Schipper HM et al., Heme oxygenase-1 in neurodegenerative disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30658837/)

[Piantadosi CA et al., Heme oxygenase-1 and brain injury (2018)](https://pubmed.ncbi.nlm.nih.gov/29558546/)

[Song W et al., Heme oxygenase-1 in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32280094/)

[Takahashi T et al., Heme oxygenase-1 gene therapy for Parkinson's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28211946/)

[Dorazio JL et al., HO-1 upregulation in Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34063289/)

[Kikuchi A et al., Heme oxygenase-1 in ALS pathogenesis (2022)](https://pubmed.ncbi.nlm.nih.gov/35131726/)

[Chen J et al., Mitochondrial HO-1 in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37164901/)

[Chang CF et al., HO-1 mediates neuroprotection in stroke (2021)](https://pubmed.ncbi.nlm.nih.gov/33539221/)

[Alam J et al., Nrf2-HO-1 pathway in cellular stress response (2022)](https://pubmed.ncbi.nlm.nih.gov/35617892/)

[Goetzl EJ et al., HO-1 polymorphisms and Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32937192/)

[Lin TK et al., Heme oxygenase-1 and Parkinson's disease (2007)](https://pubmed.ncbi.nlm.nih.gov/17880941/)

[Chung JY et al., HO-1 induction by flavonoids in neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/29529512/)

[Nath KA et al., Heme oxygenase-2 and the brain (2019)](https://pubmed.ncbi.nlm.nih.gov/30600442/)

[Wu L et al., HO-1 in traumatic brain injury (2021)](https://pubmed.ncbi.nlm.nih.gov/33720856/)

[Caldi M et al., HO-1 targeting for neurotherapeutics (2022)](https://pubmed.ncbi.nlm.nih.gov/35081745/)

[Kim DH et al., Iron metabolism and HO-1 in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37178923/)

[Peacock L et al., Astrocyte HO-1 in Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37165012/)

External Links

[UniProt P09601](https://www.uniprot.org/uniprot/P09601)
[NCBI Gene HMOX1](https://www.ncbi.nlm.nih.gov/gene/3162)
[Ensembl: ENSG00000123457](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000123457)
[GeneCards HMOX1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=HMOX1)
[OMIM 141630](https://omim.org/entry/141630)

References

[Schipper HM et al, Heme oxygenase-1 in neurodegenerative disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30658837/)

[Piantadosi CA et al, Heme oxygenase-1 and brain injury (2018)](https://pubmed.ncbi.nlm.nih.gov/29558546/)

[Song W et al, Heme oxygenase-1 in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32280094/)

[Takahashi T et al, Heme oxygenase-1 gene therapy for Parkinson's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28211946/)

[Barsoum SB et al, Heme oxygenase-1 and neuroinflammation (2019)](https://pubmed.ncbi.nlm.nih.gov/30658838/)

[Dorazio JL et al, HO-1 upregulation in Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34063289/)

[Kikuchi A et al, Heme oxygenase-1 in ALS pathogenesis (2022)](https://pubmed.ncbi.nlm.nih.gov/35131726/)

[Chen J et al, Mitochondrial HO-1 in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37164901/)

[Chang CF et al, HO-1 mediates neuroprotection in stroke (2021)](https://pubmed.ncbi.nlm.nih.gov/33539221/)

[Yoshikawa M et al, Carbon monoxide signaling in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32205020/)

[Alam J et al, Nrf2-HO-1 pathway in cellular stress response (2022)](https://pubmed.ncbi.nlm.nih.gov/35617892/)

[Goetzl EJ et al, HO-1 polymorphisms and Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32937192/)

[Lin TK et al, Heme oxygenase-1 and Parkinson's disease (2007)](https://pubmed.ncbi.nlm.nih.gov/17880941/)

[Chung JY et al, HO-1 induction by flavonoids in neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/29529512/)

[Nath KA et al, Heme oxygenase-2 and the brain (2019)](https://pubmed.ncbi.nlm.nih.gov/30600442/)

[Wu L et al, HO-1 in traumatic brain injury (2021)](https://pubmed.ncbi.nlm.nih.gov/33720856/)

[Caldi M et al, HO-1 targeting for neurotherapeutics (2022)](https://pubmed.ncbi.nlm.nih.gov/35081745/)

[Kim DH et al, Iron metabolism and HO-1 in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37178923/)

[Schipper HM et al, Heme oxygenase: a novel target for oxidative brain injury (2000)](https://pubmed.ncbi.nlm.nih.gov/10677139/)

[Xin Q et al, HO-1 and ferroptosis in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35575291/)

[Peacock L et al, Astrocyte HO-1 in Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37165012/)

📖 View canonical wiki page →

Related Entities

HEMEOXYGENASE1PROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-heme-oxygenase-1-protein
kg_node_id	HEMEOXYGENASE1PROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-76ada54243e4
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-heme-oxygenase-1-protein'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

45%

Debates

0

Incoming

9

Outgoing

11

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

heme-oxygenase-1-protein

Heme Oxygenase-1 (HO-1) Protein

Overview

Heme Oxygenase-1 (HO-1) Protein

Overview

Structure and Catalytic Mechanism

Protein Architecture

Catalytic Reaction

Normal Function in the Nervous System

Cytoprotective Functions

Cellular Distribution in the Brain

Role in Alzheimer's Disease

HO-1 Expression in AD Brain

Mechanisms of HO-1 in AD Pathogenesis

Genetic Associations

Therapeutic Implications

Role in Parkinson's Disease

HO-1 in PD Pathogenesis

Mechanisms of HO-1 in PD

Therapeutic Targeting in PD

Role in Amyotrophic Lateral Sclerosis

HO-1 Expression in ALS

Mechanisms

Role in Other Neurodegenerative Conditions

Stroke and Cerebral Ischemia

Traumatic Brain Injury

Huntington's Disease

Multiple Sclerosis and Demyelination

Ferroptosis and HO-1

Therapeutic Targeting Strategies

Pharmacological HO-1 Inducers

CO-Releasing Molecules (CORMs)

Gene Therapy Approaches

Challenges and Considerations

Key Publications and Clinical Evidence

See Also

External Links

References

💬 Discussion